• Kun Yang, Mo Xi Chen, Choi Yoon Young YY https://orcid.org/0000-0002-2179-7851 Department of Surgery, Severance Hospital, Yonsei University Health System, Yonsei University, Zong Guang Zhou, Woo Jin Hyung, Sung Hoon Noh, and Jian Kun Hu.
• Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu, China.
• Yonsei Med. J. 2021 Feb 1; 62 (2): 109-117.

PurposeThis study aimed to investigate the effectiveness of postoperative chemotherapy in pT1bN0 and pT2N0 gastric cancer patients with high risk factors.Materials And MethodsClinicopathological data of gastric cancer patients, who had undergone gastrectomy in high volume centers in Korea and China and were finally diagnosed with pT1bN0 and pT2N0 between 2006 and 2010, were analyzed retrospectively. Survival analyses stratified by risk factors and multivariable analyses were performed.ResultsA total of 1509 patients were enrolled, with 41 (2.7%) patients receiving adjuvant chemotherapy after gastrectomy and 1468 (97.3%) patients undergoing surgery alone. The adjuvant chemotherapy group showed higher percentages of tumor with maximal diameter >3 cm (51.2% vs. 25.8%), poor differentiation (68.3% vs. 49.8%), and less harvested lymph nodes (17.1% vs. 5.2%) compared to the surgery alone group. The overall survival rates were 95.1% in the adjuvant chemotherapy group and 93.3% in the surgery alone group, without significant difference. In multivariable analysis, age was found to be an independent prognostic factor. However, there were no difference in the overall survival between patients with risk factors and those without risk factors, even in terms of age. Meanwhile, patients with more than two risk factors who received chemotherapy showed better survival trend, especially for pT2N0 patients, compared to the surgery alone group, although no significant differences were observed.ConclusionIn pT1bN0 and pT2N0 patients, age was found to be an independent prognostic factor. However, adjuvant chemotherapy seemed to be unnecessary, while postoperative chemotherapy might offer survival benefits to pT2N0 patients with more than two risk factors.© Copyright: Yonsei University College of Medicine 2021.

23 keywords...

hide…